Senhwa Biosciences Launches Global Study, Targeting Breakthrough in Hard-to-Treat Cancers with CX-5461 and Tislelizumab Combination

Excerpt from the Press Release:

TAIPEI and SAN DIEGO, May 5, 2026 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company today announced the initiation of a global, multi-center clinical trial. The Company has also submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), marking a key milestone in Senhwa’s global clinical development.

The study will evaluate Senhwa’s first-in-class investigational drug, Pidnarulex (CX-5461), in combination with BeOne Medicines’ marketed PD-1 inhibitor, tislelizumab, across multiple advanced or metastatic solid tumors, including pancreatic cancer, colorectal cancer, and melanoma—areas with significant unmet medical needs. The global multi-center design is expected to accelerate clinical validation while enhancing the asset’s visibility, supporting future out-licensing and commercialization opportunities.

The Company aims to leverage combination therapy approaches to enter the rapidly expanding immuno-oncology market and build sustainable long-term growth momentum.

CX-5461 features a differentiated dual mechanism of action. In addition to inhibiting ribosomal RNA synthesis and suppressing tumor cell proliferation, it stabilizes G-quadruplex structures, inducing DNA damage and activating the cGAS–STING pathway. This unique mechanism not only confers direct anti-tumor activity but also enhances tumor immunogenicity,

Click the button below to read the entire Press Release:

Continue Reading The Press Release